DRRX

DURECT Corporation (DRRX) | Rumor.io

DURECT

DRRX

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)—

Price to earnings ratio0

Market capitalization0

Earnings per share0

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)0

Social

What share of all stock conversation is about DRRX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Jul 30

DRRX stock may be worth $2.35/sh today, considering the company's CVR ($100M at $500M/yr sales and $250M at $1B/yr sales) could add $11.27/sh in value over 5-10 years.
A conservative NPV discounting of the CVR's would give a $.60/sh premium over the $1.75 buyout price, making the current value of DRRX at least $2.35/sh.
DRRX stock has shown a remarkable day with a 260.1% gap and 32.7% run, surging on 50.4M shares, and is currently trading at $1.87.

Generated by AI

Sentiment

Of the messages about DRRX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	90.12% +40.62
Bearish	—	—	—	9.88% -40.62

Bullish· Jul 29

The acquisition of DURECT Corporation by Bausch Health could be worth $13+ per share if certain milestones are hit.
DURECT's breakthrough drug larsucosterol has received FDA Breakthrough Therapy status, indicating significant upside potential.
The company's Phase 3 trial for larsucosterol, targeting alcohol-associated hepatitis, has the potential to be approved and drive the stock price higher.

Bearish· Jul 29

The author held DRRX for 11 years and sold out around $2/share, resulting in a significant loss.
The potential for DRRX to recover is low, with some users predicting it will drop back to $0.6 or remain at $1.
Institutional investors may sell DRRX, and the author believes the stock will be delisted and go private at $1 per share.

Generated by AI

Topics

Of the messages about DRRX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Technical Analysis	—	—	—	12.97%
Macro	—	—	—	6.94%
Earnings	—	—	—	0%
Controversies	—	—	—	0%
Announcements	—	—	—	10.86%
Analysts	—	—	—	69.23%

Earnings· Jul 31

DURECT Corporation ($DRRX) is set to release earnings after the market closes on Wednesday.
Analysts expect DURECT to report earnings per share (EPS) of -0.06.
The expected EPS is based on analyst estimates.

Announcements· Jan 16

DURECT Corporation's shares were halted ahead of an FDA advisory committee meeting to discuss POSIMIR, a non-opioid pain treatment for post-surgical pain.
The FDA advisory committee was split over the approval of DURECT's non-opioid painkiller, with a decision pending.
DURECT commissioned the advisory services of Dr. Lee S. Simon to address FDA correspondence and lead the company's efforts to submit a response to the CRL for POSIMIR.

Generated by AI

Community

Of the messages about DRRX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	—	25.77%
Newcomers	—	—	—	74.23%

Regulars· Mar 7

DURECT Corporation reported a loss of $0.46 per share in Q4 2022, beating consensus estimates by $0.07.
The company's revenue for Q4 2022 was $3.31 million, missing estimates by $0.16 million.
DURECT Corporation's financial situation is precarious, with barely enough cash to cover expenses until September, and potential dilution or debt if trial results are delayed.

Newcomers· Nov 8

Newcomers to the stock are focusing on making quick profits through day trading, with some reporting gains of 70-80% or more in a short period of time.
Many newcomers are buying into $DRRX on the dip, with some citing the company's pipeline of drugs and the potential for a rebound in the stock price.
Some newcomers are citing the stock's low price and the company's strong balance sheet as reasons to buy, with one commenter noting that the stock's enterprise value is just $20M, below the cash on the balance sheet of around $25M.

Generated by AI

Also Discussed

Investors talking about DRRX also mention

#	Name	Attention
1	Rockwell Medical Inc.RMTI	0%new
2	SCYNEXIS, Inc. Common StockSCYX	0%-0.02
3	Catalyst Pharmaceuticals Inc.CPRX	0%new
4	Pacira BioSciences, Inc.PCRX	0%new
5	NAVB - Navidea Biopharmaceuticals, Inc.	——
6	MRNS - Marinus Pharmaceuticals, Inc.	——
7	Cytokinetics, IncorporatedCYTK	0.01%+0
8	ALIM - Alimera Sciences, Inc.	——
9	Geron CorporationGERN	0%0
10	Supernus Pharmaceuticals, Inc.SUPN	0%new

DURECT Corporation

Location

Social

What share of all stock conversation is about DRRX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Jul 30

DRRX stock may be worth $2.35/sh today, considering the company's CVR ($100M at $500M/yr sales and $250M at $1B/yr sales) could add $11.27/sh in value over 5-10 years.
A conservative NPV discounting of the CVR's would give a $.60/sh premium over the $1.75 buyout price, making the current value of DRRX at least $2.35/sh.
DRRX stock has shown a remarkable day with a 260.1% gap and 32.7% run, surging on 50.4M shares, and is currently trading at $1.87.

Generated by AI

Sentiment

Of the messages about DRRX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	90.12% +40.62
Bearish	—	—	—	9.88% -40.62

Bullish· Jul 29

The acquisition of DURECT Corporation by Bausch Health could be worth $13+ per share if certain milestones are hit.
DURECT's breakthrough drug larsucosterol has received FDA Breakthrough Therapy status, indicating significant upside potential.
The company's Phase 3 trial for larsucosterol, targeting alcohol-associated hepatitis, has the potential to be approved and drive the stock price higher.

Bearish· Jul 29

The author held DRRX for 11 years and sold out around $2/share, resulting in a significant loss.
The potential for DRRX to recover is low, with some users predicting it will drop back to $0.6 or remain at $1.
Institutional investors may sell DRRX, and the author believes the stock will be delisted and go private at $1 per share.

Generated by AI

Topics

Of the messages about DRRX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Technical Analysis	—	—	—	12.97%
Macro	—	—	—	6.94%
Earnings	—	—	—	0%
Controversies	—	—	—	0%
Announcements	—	—	—	10.86%
Analysts	—	—	—	69.23%

Earnings· Jul 31

DURECT Corporation ($DRRX) is set to release earnings after the market closes on Wednesday.
Analysts expect DURECT to report earnings per share (EPS) of -0.06.
The expected EPS is based on analyst estimates.

Announcements· Jan 16

DURECT Corporation's shares were halted ahead of an FDA advisory committee meeting to discuss POSIMIR, a non-opioid pain treatment for post-surgical pain.
The FDA advisory committee was split over the approval of DURECT's non-opioid painkiller, with a decision pending.
DURECT commissioned the advisory services of Dr. Lee S. Simon to address FDA correspondence and lead the company's efforts to submit a response to the CRL for POSIMIR.

Generated by AI

Community

Of the messages about DRRX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	—	25.77%
Newcomers	—	—	—	74.23%

Regulars· Mar 7

DURECT Corporation reported a loss of $0.46 per share in Q4 2022, beating consensus estimates by $0.07.
The company's revenue for Q4 2022 was $3.31 million, missing estimates by $0.16 million.
DURECT Corporation's financial situation is precarious, with barely enough cash to cover expenses until September, and potential dilution or debt if trial results are delayed.

Newcomers· Nov 8

Newcomers to the stock are focusing on making quick profits through day trading, with some reporting gains of 70-80% or more in a short period of time.
Many newcomers are buying into $DRRX on the dip, with some citing the company's pipeline of drugs and the potential for a rebound in the stock price.
Some newcomers are citing the stock's low price and the company's strong balance sheet as reasons to buy, with one commenter noting that the stock's enterprise value is just $20M, below the cash on the balance sheet of around $25M.

Generated by AI

DURECT

Social

Jul 30

Sentiment

Bullish· Jul 29

Bearish· Jul 29

Topics

Earnings· Jul 31

Announcements· Jan 16

Community

Regulars· Mar 7

Newcomers· Nov 8

Also Discussed

DURECT Corporation

Company Information

Location

Also Discussed

Social

Jul 30

Sentiment

Bullish· Jul 29

Bearish· Jul 29

Topics

Earnings· Jul 31

Announcements· Jan 16

Community

Regulars· Mar 7

Newcomers· Nov 8